Acyclic Chalcogen Bonded Directly To Ring Carbon Of The Bicyclo Ring System Patents (Class 546/116)
-
Publication number: 20030153576Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I):Type: ApplicationFiled: December 19, 2001Publication date: August 14, 2003Inventors: Albert J. Robichaud, Ian S. Mitchell
-
Patent number: 6583161Abstract: The invention provides compounds, compositions and methods relating to novel aromatic derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.Type: GrantFiled: December 12, 2000Date of Patent: June 24, 2003Assignee: Tularik Inc.Inventor: Julio C. Medina
-
Patent number: 6545021Abstract: N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulats or various combinations of such other agents.Type: GrantFiled: February 14, 2000Date of Patent: April 8, 2003Assignee: G.D. Searle & Co.Inventors: Richard A. Mueller, Martin L. Bryant, Richard A. Partis
-
Patent number: 6525197Abstract: The present invention relates to methods for preparing macrocyclic products having 9 or more ring atoms by ring-closing diyne metathesis of suitable diyne substrates. The diyne substrates can be converted into cycloalkynes or into cycloalkadiynes by cyclodimerization, depending on the particular reaction conditions. Any alkyne metathesis catalyst can be used as the catalyst, regardless of whether said catalysts are heterogeneously or homogeneously present in the reaction medium. The preferred catalysts or pre-catalysts are transition metal alkylidyne complexes, transition metal compounds which form alkylidyne complexes under the reaction conditions, and transition metal compounds with metal-metal triple bonds. The method can be carried out with numerous functional groups, solvents, and additives.Type: GrantFiled: August 4, 2000Date of Patent: February 25, 2003Assignee: Studiengesellschaft Kohle mbHInventors: Alois Fürstner, Günter Seidel, Antonio Rumbo, Christian Mathes
-
Patent number: 6511977Abstract: Indanes, benzopyrans and analogues thereof are potassium channel inhibitors and blockers of IKur and have the structure where A, B, D, Q, X1, R, R1, X2 and R2 are as defined herein. These compounds are useful as antiarrhythmic agents. In addition, a method is provided for preventing cardiac arrhythmia employing the above compounds.Type: GrantFiled: September 25, 2000Date of Patent: January 28, 2003Assignee: Bristol-Myers Squibb CompanyInventors: John Lloyd, Heather J. Finlay, Wayne Vaccaro, Karnail S. Atwal, Michael F. Gross, Kerry L. Spear
-
Patent number: 6500962Abstract: The present invention relates to a method for producing an &agr;-methylene-&ggr;-butyrolactone which is one of basic structures often shown in drugs such as an anti-cancer agent by reacting an alene compound having an aldehyde or ketone group with carbon monoxide via cyclization in a single step in the presence of a catalyst containing ruthenium, thereby improving total yield of the entire reaction and achieving effects of cost reduction.Type: GrantFiled: March 15, 2002Date of Patent: December 31, 2002Assignee: Sungkyunkwan UniversityInventors: Suk-Koo Kang, Kwang-Jin Kim
-
Patent number: 6469029Abstract: The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds having Formula I: or pharmaceutically acceptable salts thereof; wherein Q is phenyl, benzyl, pyridyl, thienyl, indolyl, quinolinyl, benzothienyl, biphenylyl, or imidazolyl; any of which can include one or more optional substituents independently selected from halo, trifluoromethyl, hydroxy, amino, nitro, cyano, C1-3 alkoxy, C1-3 alkyl, methylenedioxy, carboxamido, acetamido, or amidino; X is methylene, carbonyl, or sulfonyl; Z is methylene, ethylene, or propylene; M is methylene or ethylene; and R1 R2 and R3 are independently hydrogen or C1-3 alkyl.Type: GrantFiled: September 13, 2000Date of Patent: October 22, 2002Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Scott C. Miller, Juan José Marugán Sánchez, Kristin D. Haslow, Jonathan Hall
-
Patent number: 6444617Abstract: A fused heterocyclic dicarboxylic acid diamide derivative represented by formula (I): wherein R1 is H, (C1-C6) alkyl; R2 and R3 are H, (halo) (C1-C6) alkyl, (C3-C8) cycloalkyl, substituted amino (C1-C6) alkyl, (substituted) phenyl (C1-C6) alkyl, (substituted) phenyl (C1-C6) alkoxy or the like or R2 and R3, taken conjointly, represent a (substituted) 5- or 6-membered heterocycle having at least one of O, S and N; X is H, halogen, NO2, CN, (C1-C6) alkyl, (substituted) phenyl, (substituted) phenoxy or the like; is or the like wherein Y, R4 and R9 are H, halogen, NO2, CN, (C1-C6) alkyl or the like, and A, B, D, E, F, G, J and K are O, S, N, sulfinyl or the like; and a herbicide containing said derivative as active ingredient.Type: GrantFiled: January 26, 2001Date of Patent: September 3, 2002Assignee: Nihon Nohyaku Co., Ltd.Inventors: Hideo Takaishi, Takeshi Katsuhira, Hiroshi Yamaguchi, Youichi Kawabata, Hiroto Harayama, Yoshiki Oda, Masahiko Murai
-
Patent number: 6440993Abstract: A compound of the formula: wherein R1 and R1 and m are as defined in the specification.Type: GrantFiled: March 29, 2001Date of Patent: August 27, 2002Assignee: SmithKline Beecham CorporationInventor: Katherine L. Widdowson
-
Patent number: 6410556Abstract: Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein n, m, X, R1, R2, R3, R4, R5, R6, and R7 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.Type: GrantFiled: September 11, 2000Date of Patent: June 25, 2002Assignees: Novo Nordisk A/S, Ontogen CorporationInventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Møller, Ole Hvilsted Olsen, Frank Urban Axe, Yu Ge, Daniel Dale Holsworth, Todd Kevin Jones, Luke Milburn Judge, Wiliam Charles Ripka, Barry Zvi Shapira, Roy Teruyuki Uyeda
-
Publication number: 20020061815Abstract: Compounds of the formula I, in the form of their racemates, mixtures of stereoisomers or mainly pure stereoisomers 1Type: ApplicationFiled: April 10, 2001Publication date: May 23, 2002Inventors: Pher G. Andersson, Sofia J.M. Nordin, Peter Roth
-
Patent number: 6388077Abstract: Compounds of the general formula VI-1 and processes for their preparation: wherein t, u, v and w each independently represent a nitrogen atom or a methine group which may have a substituent selected from the group consisting of halogen, lower alkyl, lower alkoxy and optionally protected hydroxy; and wherein at least two of which represent the methine group. These compounds serve as intermediates for novel spiro compounds which exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.Type: GrantFiled: October 25, 2001Date of Patent: May 14, 2002Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takehiro Fukami, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Takahiro Itoh
-
Patent number: 6369072Abstract: This invention provides substituted compounds of the general formulae: wherein B and E are C or N; D, G and W are O, S, or N; or salt forms thereof, and methods and pharmaceutical compositions for their use in treating disorders related to insulin resistance or hyperglycemia.Type: GrantFiled: March 2, 2001Date of Patent: April 9, 2002Assignee: American Home Products CorporationInventors: Michael S. Malamas, Robert E. McDevitt, Folake O. Adebayo
-
Publication number: 20020032200Abstract: Disclosed are compounds of the formula: 1Type: ApplicationFiled: June 29, 2001Publication date: March 14, 2002Inventors: Guolin Cai, Kenneth Shaw
-
Publication number: 20020019397Abstract: The present invention provides a compound of formula I 1Type: ApplicationFiled: June 22, 2001Publication date: February 14, 2002Applicant: Pharmacia & Upjohn CompanyInventors: Mark E. Schnute, Valerie A. Vaillancourt, Scott D. Larsen
-
Publication number: 20020019412Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: ApplicationFiled: March 9, 1999Publication date: February 14, 2002Inventors: HENRIK SUNE ANDERSEN, TODD KEVIN JONES, DANIEL DALE HOLSWORTH
-
Patent number: 6339085Abstract: Pyridoxal analogues can be useful for treating B6 efficiency and related diseases; cardiovascular and related diseases; melanoma and related diseases; and symptoms thereof. One such analogue is a compound of the formula: or a pharmaceutically acceptable acid addition salt thereof, in which R1 is alkyl, alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy; alkoxy; dialkylamino; alkanoyloxy; alkanoyloxyaryl; alkoxyalkanoyl; alkoxycarbonyl; dialkylcarbamoyloxy; or aryl, aryloxy, arylthio, or aralkyl, in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy, halo, nito, or alkanoyloxy. These analogues can be administered, either alone or concurrently with known medications, to treat the above-described diseases.Type: GrantFiled: March 7, 2000Date of Patent: January 15, 2002Assignees: The University of Manitoba, Medicore Inc.Inventor: Wasimul Haque
-
Patent number: 6339092Abstract: A compound selected from those of the formula (I): wherein: R1 represents hydrogen or halogen, or alkyl or alkoxy, R2 represents hydroxy, alkoxy or —NHOH, Ar1 represents phenylene or biphenylene, X represents oxygen or sulphur, NR, —C≡C— or a bond, R represents hydrogen or alkyl, n is an integer from 0 to 6 inclusive, Ar2 represents any one of the groups as defined in the description, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as metalloprotease inhibitors.Type: GrantFiled: June 30, 2000Date of Patent: January 15, 2002Assignee: Adir et CompagnieInventors: Guillaume de Nanteuil, Alain Benoist, Jacqueline Bonnet, Massimo Sabatini, Ghanem Atassi, Alain Pierre
-
Patent number: 6335345Abstract: Spiro compounds of the general formula (I): wherein Ar1 represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.Type: GrantFiled: August 14, 2001Date of Patent: January 1, 2002Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takehiro Fukami, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Takahiro Itoh
-
Patent number: 6313138Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: February 20, 2001Date of Patent: November 6, 2001Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hartman
-
Patent number: 6310074Abstract: The invention relates to compound of formula (I): A—G1—Cy—G2—Cy′—G3—B (I) wherein: A represents a grouping NR1C(Q)R2, C(Q)NR2R3 or NR1C(Q)NR2R3, B represents a grouping NR1C(Q)R2, NR1C(Q)NR2R3, C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2 or NR2R3, G1 and G3 represent an optionally substituted alkylene chain, Cy and Cy′, which are different, represent a ring structure or G2 represents a chain and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.Type: GrantFiled: May 18, 2000Date of Patent: October 30, 2001Assignee: Adir et CompagnieInventors: Patrick Depreux, Said Yous, Gwenael Cheve, Gérald Guillaumet, Marie-Claude Viaud, Carlos Larraya, Caroline Bennejean, Philippe Delagrange, Pierre Renard, Carole Descamps-Francois
-
Patent number: 6306874Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: October 17, 2000Date of Patent: October 23, 2001Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
-
Patent number: 6284891Abstract: The present invention relates to a process for preparing camptothecin and camptothecin analogs of Formula (I) from compounds of Formula (II) and to novel intermediates useful in their preparation, wherein R1 to R6 represent various substituents.Type: GrantFiled: August 15, 2000Date of Patent: September 4, 2001Assignee: Gilead Sciences, Inc.Inventors: Francis Gerard Fang, Shiping Xie
-
Patent number: 6277860Abstract: This invention provides a compound of formula (I): or pharmaceutically acceptable salts thereof, wherein X1 and X2 are C or N, respectively; R1 and R2 are independently phenyl optionally substituted with a hydroxy group with proviso that X1 and X2 are not simultaneously C or N, when X1 is N, R1 is absent, and when X2 is N, R2 is absent; R3 is methyl or hydroxymethyl; R4 is formyl, hydroxymethyl or hydroxy C3-6 alkenyl; R5 is hydroxy, C3-6 alkenyl or hydroxy C3-6 alkenyl; or R4 and R5, together with the carbon atoms in the furopyridine ring to which they are attached, may form the following ring (to be fused with the furopyridine ring): with the proviso that when R3 is methyl and R5 is 2-buten-2-yl, X2 is not N. These compounds and pharmaceutical compositions containing such compounds are useful for treating infectious diseases caused by bacteria.Type: GrantFiled: October 29, 1999Date of Patent: August 21, 2001Assignee: Pfizer IncInventors: Yutaka Sugie, Akemi Sugiura, Nobuji Yoshikawa, Susan J. I Truesdell, John W. Wong
-
Patent number: 6265580Abstract: A pyridine alcohol derivative represented by General Formula III (where A represents a divalent organic group which may contain one to three oxygen atoms, nitrogen atoms and/or sulfur atoms, wherein A may form a 5-, 6-, 7-, or 8-membered ring together with two bonded carbon atoms, where said ring may form a condensed ring with one or more additional rings; R5 represents a hydrogen atom, —CHR1R2, or an alkenyl group, an aryl group or an aralkyl group which may be substituted; R1 and R2 each independently represent a hydrogen atom or a hydrocarbon group which may be substituted; and R6 represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group which may be substituted), is produced by: reacting a pyridine ester derivative represented by General Formula I-1 (where Z1 represents —COX; X represents an alkoxyl group, an alkenyloxy group, an aryloxy group or an aralkyloxy group which may be substituted; and A is the same as aType: GrantFiled: March 17, 2000Date of Patent: July 24, 2001Assignee: Kuraray Co., Ltd.Inventors: Hideki Matsuda, Goro Asanuma, Takanobu Shin, Manzo Shiono, Shigeki Kikuyama
-
Patent number: 6229011Abstract: Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.Type: GrantFiled: August 21, 1998Date of Patent: May 8, 2001Assignee: Hoffman-La Roche Inc.Inventors: Li Chen, Robert William Guthrie, Tai-Nang Huang, Achyutharao Sidduri, Jefferson Wright Tilley, Kenneth Gregory Hull
-
Patent number: 6211371Abstract: A method of synthesizing compounds having the formula via a 4+1 radical annulation/cyclization wherein the precursor is reacted with an aryl isonitrile having the formula wherein X is selected from the group consisting of Br and I, ≡Y is ≡N or ≡C—R3, R1, R2, and R6 are independently hydrogen, a normal alkyl group, a branched alkyl group, an allyl group, a benzyl group, an alkynyl group, a propargyl group, an alkoxyl group, a halogen group, a trialkylsilyl group, an amino group, an alkyl amino group, a dialkylamino group, an aminoalkyl group, a cyano group, or R16CO—, wherein R16 is an alkyl group, an alkoxyl group, or an amino group, R3 is hydrogen, a normal alkyl group, a branched alkyl group, an allyl group, a benzyl group, an alkynyl group, a propargyl group, an alkoxyl group, a halogen group, a trialkylsilyl group, an amino group, an alkyl amino group, a dialkylamino group, an aminoalkyl group, a cyano group, or R16COType: GrantFiled: January 15, 1998Date of Patent: April 3, 2001Assignee: University of PittsburghInventors: Dennis P. Curran, Hubert Josien, Sung Bo Ko
-
Patent number: 6194428Abstract: The invention relates to the use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives, some of which are known, for the production of medicaments, in particular for the treatment of cerebral disorders.Type: GrantFiled: January 28, 1999Date of Patent: February 27, 2001Assignee: Bayer AktiengesellschaftInventors: Klaus Urbahns, Hans-Georg Heine, Bodo Junge, Rudolf Schohe-Loop, Henning Sommermeyer, Thomas Glaser, Reilinde Wittka, Jean-Marie-Viktor de Vry
-
Patent number: 6169092Abstract: 3-Urea-pyridofurans and -pyridothiophenes are prepared by reacting appropriately substituted 3-amino-pyridofurans or -pyridothiophenes with isocyanates or isothiocyanates. The 3-urea-pyridofurans and -pyridothiophenes can be used as active ingredients in medicaments, particularly in medicaments for the treatment of acute and chronic inflammatory processes.Type: GrantFiled: January 5, 1999Date of Patent: January 2, 2001Assignee: Bayer AktiengesellschaftInventors: Gabriele Br{umlaut over (a)}unlich, Mazen Es-Sayed, R{umlaut over (u)}diger Fischer, Rolf Henning, Burkhard Fugmann, Stephan Schneider, Michael Sperzel, Graham Sturton, Mary Fitzgerald, Barbara Briggs, Arnel Concepcion
-
Patent number: 6169090Abstract: The compound, according to formula (i) wherein X and Y are independently CH, N or N-oxide, provided that X and Y do not both represent CH; Z is CO or CS; R1 is alkyl, optionally substituted with one or more halogens; and R2, R3, R4 and R5 are each various organic groups. Such compounds have therapeutic utility, via inhibition of phosphodiesterase IV.Type: GrantFiled: June 8, 1999Date of Patent: January 2, 2001Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, Verity Margaret Sabin, Andrew Sharpe, Alan Findlay Haughan, Christopher Lowe, George Buckley, John Montana
-
Patent number: 6159975Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.Type: GrantFiled: February 10, 1999Date of Patent: December 12, 2000Assignee: Merck & Co., Inc.Inventors: Jonathan R. Young, Thomas F. Walsh, Mark T. Goulet, Michael H. Fisher
-
Patent number: 6153645Abstract: Methods for treating infection and related compositions, compounds of formula I as defined in the application and methods for preparing same, are provided. In general, the compounds inhibit transfer ribonucleic acid (tRNA) synthetase and are useful as antimicrobial agents.Type: GrantFiled: September 10, 1999Date of Patent: November 28, 2000Assignee: Cubist Pharmaceuticals, Inc.Inventors: John Finn, Xiang Yang Yu, Zhongguo Wang, Jason Hill, Dennis Keith, Paul Gallant, Philip Wendler
-
Patent number: 6143761Abstract: Compounds corresponding to the general formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom, a (C.sub.1 -C.sub.6)alkyl group or a phenyl(C.sub.1 -C.sub.4)alkyl group, R.sub.2 represents a hydrogen atom or a (C.sub.1 -C.sub.6)alkyl group and R.sub.3, R.sub.4 and R.sub.5 each represent, independently of one another, a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxyl, (C.sub.1 -C.sub.6)alkyl or (C.sub.1 -C.sub.6)alkoxy group. Application in therapeutics.Type: GrantFiled: September 15, 1999Date of Patent: November 7, 2000Assignee: Sanofi-SynthelaboInventors: Alistair Lochead, Samir Jegham, Frederic Galli, Thierry Gallet
-
Patent number: 6121451Abstract: This invention relates to intermediates and processes for the synthesis of camtothecin derivatives, such as irinotecan. Related procedures and compounds are disclosed, such as a method of making mappicine.Type: GrantFiled: October 2, 1997Date of Patent: September 19, 2000Assignee: Pharmacia & Upjohn CompanyInventors: Kevin E. Henegar, John C. Sih
-
Patent number: 6096771Abstract: An isoxazole compound having the following formula: ##STR1## wherein R.sup.1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R.sup.2 represents an amino; m is 2 or 3; n is 1 to 6; ring A represents a phenyl ring, a naphthyl ring or an aromatic heterocycle; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.Type: GrantFiled: February 3, 1999Date of Patent: August 1, 2000Assignee: Sankyo Company, LimitedInventors: Koichi Kojima, Junichi Sakai, Yuichi Aizawa, Naozumi Samata, Masao Kozuka, Kenji Yoshimi, Isao Kaneko, Kazuo Koyama
-
Patent number: 6069151Abstract: Compounds of the formula ##STR1## have therapeutic utility, as inhibitors of phosphodiesterase IV and TNF release.Type: GrantFiled: June 17, 1998Date of Patent: May 30, 2000Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, John Gary Montana, Alan Findlay Haughan, Verity Margaret Sabin
-
Patent number: 6025366Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.Type: GrantFiled: March 25, 1999Date of Patent: February 15, 2000Assignee: Merck & Co., Inc.Inventors: Thomas F. Walsh, Mark T. Goulet, Feroze Ujjainwalla, Jonathan R. Young
-
Patent number: 6015824Abstract: The present invention relates to the use of pyrrolidine and piperidine derivatives of the general formula ##STR1## wherein R.sup.1 and R.sup.2 are, independently from each other, hydrogen, lower alkoxy, hydroxy, halogen, --CONH.sub.2 or --C(O)O-lower alkyl; or taken together are --O--CH.sub.2 O;R.sup.3 and R.sup.4 are, independently from each other, hydrogen, lower alkoxy, benzyloxy, halogen, hydroxy, --CONH.sub.2 or --SCH.sub.3 ; or taken together are --O--CH.sub.2 --O--;Y is --CH(OH)--, --(CH.sub.2).sub.n --, --C(O)-- or --CH(lower alkoxy)--; andm, n and p are 1 or 2;and to their pharmaceutically acceptable addition salts for the treatment of diseases caused by over activation of NMDA receptor subtypes.Type: GrantFiled: January 20, 1999Date of Patent: January 18, 2000Assignee: Hoffmann-La Roche AGInventors: Alexander Alanine, Bernd Buttelmann, Marie-Paule Heitz Neidhart, Emmanuel Pinard, Rene Wyler
-
Patent number: 6013655Abstract: Methods, compositions, and compounds for modulating the activity of an endothelin pepuide are provided. The methods use compositions that contain compounds that include those of the formula: ##STR1## where X is selected from groups that include O, S, and NH; Y is selected from O.sup.+ and N, and R.sup.1 and R.sup.2 are each selected independently from among alkyl, lower allkenyl, lower alkynyl, lower haloalkyl, halide, pseudohalide or H, except that R.sup.2 is not halide. R.sup.3, R.sup.4 and R.sup.5 are selected from among groups that include hydrogen, halide, alkoxy, alkyl, haloalkyl; and R.sup.7 is selected from groups that include (CH.sub.2).sub.r R.sup.18, in which r is 0 to 6 and R.sup.18 is selected from groups that include aryl, particularly pyrimidinyl and phenyl.Type: GrantFiled: September 4, 1998Date of Patent: January 11, 2000Assignee: Texas Biotechnology CorporationInventor: Erik Joel Verner
-
Patent number: 6001849Abstract: Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.Type: GrantFiled: April 11, 1997Date of Patent: December 14, 1999Assignee: Abbott LaboratoriesInventors: Richard L. Elliott, Keith B. Ryther, Mark W. Holladay, James T. Wasicak, Jerome F. Daanen, Nan-Horng Lin, Michael J. Dart, Yun He, Yihong Li
-
Patent number: 5994321Abstract: A series of guanine analogs and physiological salts thereof, which are useful as virus inhibitors and as antiviral agents in the treatment of viral disease, having the basic structures of: ##STR1## wherein B is H, CH.sub.3 or NH.sub.2 ; C is NH.sub.2 or SCH.sub.3 ; D is N or CH; E is O, S or Se; and G is selected from a group consisting of alkanes, alkenes, ethers, esters, hydrocarbons, amines and heterocyclic compounds, is herein disclosed. In I and III, A is O, S or Se while in II, A is NH.sub.2, OH, NHOH, OCH.sub.3 or SCH.sub.3. In I and II, F is 0, S or Se, while in III, F is F is 0, S, Se or NH. These compounds may be formulated with a physiological carrier, and used either alone or in combination with, for example, acyclovir or ganciclovir or another therapeutic agent, for the treatment of conditions resulting from viral infections.Type: GrantFiled: June 10, 1997Date of Patent: November 30, 1999Assignee: Aronex Pharmaceuticals, Inc.Inventors: Arthur F. Lewis, Ganapathi R. Revankar
-
Patent number: 5965591Abstract: An isoxazole compound having the following formula: wherein R.sup.1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R.sup.2 represents an amino; m is 1; n is 1 to 6; ring A represents a phenyl ring or a naphthyl ring; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.Type: GrantFiled: February 26, 1997Date of Patent: October 12, 1999Assignee: Sankyo Company, LimitedInventors: Koichi Kojima, Junichi Sakai, Yuichi Aizawa, Naozumi Samata, Masao Kozuka, Kenji Yoshimi, Isao Kaneko, Kazuo Koyama
-
Patent number: 5962469Abstract: The present invention is directed to novel cyclic nitrones and their use in the prevention of oxidation tissue damage by free radicals, their use in the treatment of a number of disease states in which radicals either damage or destroy tissues via oxidation, and pharmaceutical compositions containing these cyclic nitrones.Type: GrantFiled: November 26, 1997Date of Patent: October 5, 1999Assignee: Hoechst Marion Roussel Inc.Inventors: Craig E. Thomas, Thomas L. Fevig, Stephen M. Bowen, Robert A. Farr, Albert A. Carr, David A. Janowick
-
Patent number: 5932587Abstract: The heterocyclic-fused pyridines are prepared by reaction of the corresponding heterocyclic-fused pyridine aldehydes with appropriately substituted Grignard or Wittig reagents. The heterocyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of dislipidaemia and arteriosclerosis.Type: GrantFiled: June 27, 1997Date of Patent: August 3, 1999Assignee: Bayer AktiengesellschaftInventors: Carsten Schmeck, Matthias Muller-Gliemann, Gunter Schmidt, Arndt Brandes, Rolf Angerbauer, Michael Logers, Klaus-Dieter Bremm, Hilmar Bischoff, Delf Schmidt, Joachim Schuhmacher
-
Patent number: 5925653Abstract: Substituted pyridines and pyrimidines, processes for their preparation and their use as pesticides and fungicides.The invention relates to compounds of the formula ##STR1## in which A is N or CH, R is H, halogen, alkyl or cycloalkyl, R.sup.2 and R.sup.3 are H, halogen or an aliphatic radical or together form a ring, X is O, NH or S(O).sub.q where q=0, 1 of 2, R.sup.4.sub.q is 0-4 radicals selected from the series consisting of halogen, optionally substituted alkyl or alkoxy, cycloalkyl and optionally substituted phenyl, n=0-2, m=1-3 and Y is optionally substituted methylene or imino.The invention furthermore relates to a process for their preparation and for their use as pesticides, in particular as insecticides, acaricides and fungicides. The compounds are furthermore suitable for controlling nematodes, helminths and molluscs, and for controlling endoparasites and ectoparasites in the field of veterinary medicine.Type: GrantFiled: September 6, 1996Date of Patent: July 20, 1999Assignee: Hoechst Schering AgrEvo GmbHInventors: Rainer Preuss, Wolfgang Schaper, Martin Markl, Harald Jakobi, Peter Braun, Werner Knauf, Burkhard Sachse, Anna Waltersdorfer, Manfred Kern, Peter Lummen, Werner Bonin
-
Patent number: 5919955Abstract: The present invention relates to a process for the generation of a plurality of different benzofuran derivatives, and to the use of said benzofuran derivatives to search for novel classes of compounds and individual compounds possessing selected properties for pharmaceutical applications.Type: GrantFiled: January 13, 1998Date of Patent: July 6, 1999Assignee: Pharmacia & Upjohn S.p.A.Inventors: Daniele Fancelli, Dino Severino, Maria Chiara Fagnola, Angelo Bedeschi
-
Patent number: 5874382Abstract: Compounds of Formula I and II, and their agriculturally-suitable salts, are disclosed which are useful for controlling undesired vegetation ##STR1## wherein X is a direct bond; O; S; NH; N(C.sub.1 -C.sub.3 alkyl); N(C.sub.1 -C.sub.3 haloalkyl); or N(allyl);R.sup.1 is H; F; Cl; or Br;R.sup.2 is H; F; Cl; Br; CF.sub.3 ; nitro; or cyano;R.sup.4 is H; C.sub.1 -C.sub.3 alkyl; or halogen;R.sup.5 is H; C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 haloalkyl; halogen; S(O).sub.2 (C.sub.1 -C.sub.6 alkyl); or C(.dbd.O)R.sup.8 ; orR.sup.4 and R.sup.5 are taken together along with the carbon to which they are attached to form a spiro-cyclopropane ring;and R.sup.3, R.sup.8, and J are as defined in the disclosure.Also disclosed are compositions containing the compounds of Formulae I and II and a method for controlling undesired vegetation which involves contacting the vegetation or its environment with an effective amount of a compound of Formula I or II.Type: GrantFiled: January 23, 1998Date of Patent: February 23, 1999Assignee: E. I. du Pont de Nemours and CompanyInventors: Balreddy Kamireddy, William Mark Murray
-
Patent number: 5866587Abstract: Compound of formula (I): ##STR1## in which: m, n, which are identical or different, represent 0, 1 or 2,R.sub.1, R.sub.2, which are identical or different, represent hydrogen, optionally substituted alkyl, aryl, or form with the carbon atom carrying them carbonyl or (C.sub.3 -C.sub.7)cycloalkyl,R.sub.3 represents hydrogen, alkyl, hydroxyl or aryl,R.sub.4 represents any of the groups as defined in the description,X represents --SO.sub.2 --, --CO-- or --SO.sub.2 NH--,R.sub.5 represents optionally substituted alkyl, (C.sub.3 -C.sub.7)cycloalkyl, aryl or heterocyclic,A represents an aryl ring or a heterocycle,its isomers as well as its addition salts with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as metalloprotease inhibitors.Type: GrantFiled: April 25, 1997Date of Patent: February 2, 1999Assignee: Adir Et CompagnieInventors: Guillaume de Nanteuil, Joseph Paladino, Georges Remond, Ghanem Atassi, Alain Pierre, Gordon Tucker, Jacqueline Bonnet, Massimo Sabatini
-
Patent number: 5843989Abstract: The invention provides certain 5 and/or 8 substituted benzopyran, pyranopyridine or tetrahydroquinaline compounds having C.sub.4 -amide substituent and processes for making them. The compounds described are useful in treating and/or preventing certain disorders.Type: GrantFiled: December 10, 1996Date of Patent: December 1, 1998Assignee: SmithKline Beecham p.l.c.Inventors: Antonio Kuok Keong Vong, Mervyn Thompson, John Morris Evans, Helen Kate Ann Morgan
-
Patent number: 5844102Abstract: A compound of the formula ##STR1## wherein n, m, and p, which may be the same or different, are a number between 0 and 5; q is a number between 0 and 10; R.sub.1, R.sub.2 R.sub.3 R.sub.4 and R.sub.5, which may be the same or different, are a hydrogen, a hydroxyl, a halogen, a hydrocarbon or an O-hydrocarbon group having between 1 and 6 carbons which is aliphatic, alicyclic or aromatic, or a glycosyl group; and R.sub.4 is a glycosyl group, is disclosed. Nitrogen oxides of such compounds are also included. These novel compounds have been found to be potent glycohydrolase inhibitors. Processes for preparing these novel compounds and methods for their use in the treatment of diabetes mellitus are also provided.Type: GrantFiled: September 7, 1994Date of Patent: December 1, 1998Assignee: University of Maryland Baltimore CountyInventors: Michael R. Sierks, Mikael Bols, Troels Skrydstrup